Axsome Therapeutics (AXSM) Financials

$103.98 -1.09 (-1.04%)

Closing price 05/27/2025 04:00 PM Eastern

Extended Trading

$107.30 +3.32 (+3.19%)

As of 05/27/2025 05:15 PM Eastern

Annual Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12
Consolidated Net Income / (Loss)	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12
Net Income / (Loss) Continuing Operations	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12
Total Pre-Tax Income	-287	-238	-187	-130	-103	-68	-31	-29	-28	-12
Total Operating Income	-281	-232	-180	-125	-99	-67	-33	-27	-28	-9.20
Total Gross Profit	352	245	45	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Revenue	386	271	50	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Revenue	386	271	50	0.00	0.00	-	-	-	-	-
Total Cost of Revenue	33	26	5.20	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	33	26	5.20	0.00	0.00	-	-	-	-	-
Total Operating Expenses	633	476	225	125	99	67	33	27	28	9.20
Selling, General & Admin Expense	411	323	159	67	29	14	9.35	7.21	6.34	2.42
Research & Development Expense	187	98	58	58	70	54	23	20	21	6.78
Amortization Expense	6.39	6.38	4.14	0.00	0.00	-	-	-	-	-
Other Operating Expenses / (Income)	28	49	3.30	0.00	0.00	-	-	-	-	-
Total Other Income / (Expense), net	-6.57	-6.45	-7.34	-5.70	-3.81	-1.24	1.66	-1.99	-0.13	-3.29
Interest & Investment Income	-6.57	-6.45	-7.34	-5.70	-2.57	-1.24	-1.13	-1.34	-0.13	-0.74
Income Tax Expense	0.09	0.96	0.00	0.00	-0.05	-	-0.22	-	-	-
Other Gains / (Losses), net	0.00	0.00	0.00	0.00	-	0.14	-	0.21	0.47	0.00
Basic Earnings per Share	($5.99)	($5.27)	($4.60)	($3.47)	($2.77)	($2.01)	($1.15)	($1.27)	($1.42)	($1.02)
Weighted Average Basic Shares Outstanding	47.91M	45.43M	40.66M	37.62M	37.21M	34.02M	26.88M	22.76M	19.15M	11.95M
Diluted Earnings per Share	($5.99)	($5.27)	($4.60)	($3.47)	($2.77)	($2.01)	($1.15)	($1.27)	($1.42)	($1.02)
Weighted Average Diluted Shares Outstanding	47.91M	45.43M	40.66M	37.62M	37.21M	34.02M	26.88M	22.76M	19.15M	11.95M
Weighted Average Basic & Diluted Shares Outstanding	48.77M	47.37M	43.52M	37.62M	37.21M	34.02M	26.88M	22.76M	19.15M	11.95M

This table shows Axsome Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
Consolidated Net Income / (Loss)	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
Net Income / (Loss) Continuing Operations	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
Total Pre-Tax Income	-59	-75	-65	-79	-68	-99	-63	-68	-8.64	-61	-45
Total Operating Income	-57	-73	-63	-78	-67	-98	-62	-65	-6.37	-60	-42
Total Gross Profit	112	108	96	79	69	64	51	42	87	22	15
Total Revenue	121	119	105	87	75	72	58	47	95	24	17
Operating Revenue	121	119	105	87	75	72	58	47	95	24	17
Total Cost of Revenue	9.79	11	8.44	8.06	6.30	7.38	6.53	4.60	7.56	2.29	1.92
Operating Cost of Revenue	9.79	11	8.44	8.06	6.30	7.38	6.53	4.60	7.56	2.29	1.92
Total Operating Expenses	169	181	159	157	136	162	113	107	93	82	57
Selling, General & Admin Expense	121	113	96	104	99	87	83	79	74	61	41
Research & Development Expense	45	55	45	50	37	31	29	21	18	15	15
Amortization Expense	1.57	1.61	1.61	1.59	1.59	1.61	1.61	1.59	1.57	1.61	1.61
Other Operating Expenses / (Income)	1.51	11	16	2.16	-1.41	43	-0.18	6.05	-0.16	4.20	-0.04
Total Other Income / (Expense), net	-2.43	-2.21	-1.98	-1.30	-1.08	-0.70	-0.76	-2.73	-2.26	-1.32	-2.41
Interest & Investment Income	-2.43	-2.21	-1.98	-1.30	-1.08	-0.70	-0.76	-2.73	-2.26	-1.32	-2.41
Income Tax Expense	0.00	0.09	0.00	0.00	0.00	-0.33	-0.68	-0.62	2.58	-	0.00
Basic Earnings per Share	($1.22)	($1.54)	($1.34)	($1.67)	($1.44)	($2.15)	($1.32)	($1.54)	($0.26)	($1.44)	($1.07)
Weighted Average Basic Shares Outstanding	48.87M	47.91M	48.14M	47.57M	47.39M	45.43M	47.12M	43.67M	43.52M	40.66M	41.70M
Diluted Earnings per Share	($1.22)	($1.54)	($1.34)	($1.67)	($1.44)	($2.15)	($1.32)	($1.54)	($0.26)	($1.44)	($1.07)
Weighted Average Diluted Shares Outstanding	48.87M	47.91M	48.14M	47.57M	47.39M	45.43M	47.12M	43.67M	43.52M	40.66M	41.70M
Weighted Average Basic & Diluted Shares Outstanding	49.24M	48.77M	48.46M	48.00M	47.50M	47.37M	47.32M	47.19M	43.57M	43.52M	43.43M

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	-71	185	114	-97	-36	206	-20	-2.60	-11	45
Net Cash From Operating Activities	-128	-145	-117	-108	-78	-46	-30	-26	-21	-7.44
Net Cash From Continuing Operating Activities	-128	-145	-117	-108	-78	-46	-30	-26	-21	-7.44
Net Income / (Loss) Continuing Operations	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12
Consolidated Net Income / (Loss)	-287	-239	-187	-130	-103	-68	-31	-29	-27	-12
Depreciation Expense	0.53	0.46	0.26	0.08	0.02	0.04	0.05	0.04	0.02	0.00
Amortization Expense	10	8.95	5.62	1.08	0.84	0.65	0.38	0.47	0.07	0.05
Non-Cash Adjustments To Reconcile Net Income	114	113	41	21	23	6.12	-1.04	2.72	2.03	3.78
Changes in Operating Assets and Liabilities, net	34	-28	24	0.32	0.41	15	1.52	-0.81	3.80	0.94
Net Cash From Investing Activities	-0.27	-0.58	-54	-0.31	-0.05	-0.02	-0.03	-0.01	-0.10	-0.02
Net Cash From Continuing Investing Activities	-0.27	-0.58	-54	-0.31	-0.05	-0.02	-0.03	-0.01	-0.10	-0.02
Purchase of Property, Plant & Equipment	-0.27	-0.58	-0.70	-0.31	-0.05	-0.02	-0.03	-0.01	-0.10	-0.02
Acquisitions	0.00	0.00	-53	0.00	0.00	-	-	-	-	-
Net Cash From Financing Activities	58	331	285	11	42	252	10	24	9.97	53
Net Cash From Continuing Financing Activities	58	331	285	11	42	252	10	24	9.97	53
Repayment of Debt	0.00	-1.44	-0.49	-0.31	-23	-7.24	-3.36	-0.28	-0.06	0.00
Repurchase of Common Equity	-0.82	-16	-6.98	-0.22	-	0.00	-	-	-	-
Issuance of Debt	0.00	85	45	0.00	50	20	0.00	0.00	10	7.44
Issuance of Common Equity	71	259	250	7.44	14	238	13	24	0.00	46
Other Financing Activities, net	-13	4.37	-2.97	4.23	1.05	1.39	0.51	0.48	0.03	0.00
Cash Interest Paid	20	17	7.69	4.63	2.10	1.29	0.77	0.87	0.05	-

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-14	-12	12	-16	-55	-30	-21	191	46	-27	154
Net Cash From Operating Activities	-43	-26	-19	-30	-53	-30	-54	-55	-5.82	-28	-23
Net Cash From Continuing Operating Activities	-43	-26	-19	-30	-53	-30	-54	-55	-5.82	-28	-23
Net Income / (Loss) Continuing Operations	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
Consolidated Net Income / (Loss)	-59	-75	-65	-79	-68	-99	-62	-67	-11	-61	-45
Depreciation Expense	0.15	0.13	0.13	0.14	0.13	0.13	0.14	0.10	0.09	0.09	0.07
Amortization Expense	2.65	2.65	2.60	2.49	2.32	2.06	2.23	2.50	2.16	1.95	2.06
Non-Cash Adjustments To Reconcile Net Income	23	33	38	24	19	63	15	23	13	15	8.67
Changes in Operating Assets and Liabilities, net	-10	13	5.08	23	-6.81	3.43	-8.66	-14	-9.63	17	11
Net Cash From Investing Activities	-0.34	-0.03	-0.09	-0.05	-0.10	-0.01	-0.37	-0.13	-0.07	-0.18	-0.07
Net Cash From Continuing Investing Activities	-0.34	-0.03	-0.09	-0.05	-0.10	-0.01	-0.37	-0.13	-0.07	-0.18	-0.07
Purchase of Property, Plant & Equipment	-0.34	-0.03	-0.09	-0.05	-0.10	-0.01	-0.37	-0.13	-0.07	-0.18	-0.07
Net Cash From Financing Activities	29	14	30	14	-1.19	-0.00	33	246	52	1.07	177
Net Cash From Continuing Financing Activities	29	14	30	14	-1.19	-0.00	33	246	52	1.07	177
Repurchase of Common Equity	-0.39	-0.33	-0.26	-	-	-	-2.05	-	-	-	-5.22
Issuance of Common Equity	20	18	43	-	-	-11	45	-	-	6.25	180
Other Financing Activities, net	10	-2.99	-12	3.34	-1.19	10	-8.75	4.93	-2.22	-5.19	1.97
Cash Interest Paid	4.59	4.76	5.02	5.01	4.90	4.87	4.73	3.92	3.22	2.57	2.53

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	568	588	331	88	186	221	15	36	38	49
Total Current Assets	485	504	246	87	184	220	15	35	38	49
Cash & Equivalents	315	386	201	86	184	220	14	34	37	48
Accounts Receivable	142	95	38	0.00	-	-	-	-	-	-
Inventories, net	16	15	4.32	0.00	-	-	-	-	-	-
Prepaid Expenses	12	8.12	2.78	0.05	0.15	0.41	1.25	1.28	1.38	1.00
Plant, Property, & Equipment, net	0.58	0.85	0.72	0.28	0.05	0.03	0.05	0.07	0.10	0.02
Total Noncurrent Assets	83	83	85	0.98	2.06	0.14	0.11	0.19	0.11	0.03
Goodwill	12	12	10	0.00	-	-	-	-	-	-
Intangible Assets	47	53	60	0.00	-	-	-	-	-	-
Other Noncurrent Operating Assets	24	18	15	0.98	2.06	0.14	0.11	0.19	0.11	0.03
Total Liabilities & Shareholders' Equity	568	588	331	88	186	221	15	36	38	49
Total Liabilities	511	397	222	72	72	42	14	19	17	2.63
Total Current Liabilities	230	139	97	23	23	24	11	12	7.17	2.63
Short-Term Debt	8.29	6.41	5.90	0.00	-	2.60	3.29	3.27	0.27	0.00
Accounts Payable	220	131	90	22	22	22	7.53	6.11	6.90	2.63
Other Current Liabilities	1.84	1.27	0.43	0.62	1.22	0.00	-	2.79	0.00	-
Total Noncurrent Liabilities	281	258	125	49	49	17	3.62	6.66	9.47	0.00
Long-Term Debt	181	178	94	49	48	17	3.62	6.66	9.47	0.00
Capital Lease Obligations	2.94	0.00	-	-	-	-	-	-	-	-
Other Noncurrent Operating Liabilities	98	80	31	0.00	0.58	0.00	-	-	-	-
Total Equity & Noncontrolling Interests	57	191	110	16	114	179	0.94	17	22	46
Total Preferred & Common Equity	57	191	110	16	114	179	0.94	17	22	46
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-
Total Common Equity	57	191	110	16	114	179	0.94	17	22	46
Common Stock	1,180	1,027	706	425	393	355	108	93	69	67
Retained Earnings	-1,123	-836	-596	-409	-279	-176	-108	-77	-48	-20

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	597	561	548	546	601	612	389	339
Total Current Assets	495	479	463	460	512	520	304	252
Cash & Equivalents	301	327	316	331	417	437	247	228
Accounts Receivable	161	124	120	101	78	67	45	20
Inventories, net	16	14	15	16	9.99	9.25	7.94	2.10
Prepaid Expenses	16	13	12	12	6.80	5.91	5.20	2.46
Plant, Property, & Equipment, net	0.77	0.68	0.72	0.81	0.97	0.74	0.70	0.63
Total Noncurrent Assets	101	82	84	84	88	91	84	86
Goodwill	12	12	12	12	12	12	10	12
Intangible Assets	45	49	50	52	55	57	58	61
Other Noncurrent Operating Assets	44	21	22	21	21	23	16	13
Total Liabilities & Shareholders' Equity	597	561	548	546	601	612	389	339
Total Liabilities	543	469	445	402	331	333	277	182
Total Current Liabilities	244	196	187	144	115	115	101	60
Short-Term Debt	8.60	8.13	7.04	6.39	6.67	6.34	6.00	7.00
Accounts Payable	235	186	178	137	108	108	95	53
Other Current Liabilities	0.45	1.63	1.42	1.15	0.44	0.35	0.11	0.42
Total Noncurrent Liabilities	300	272	259	258	217	218	177	121
Long-Term Debt	181	180	179	179	177	177	148	94
Capital Lease Obligations	3.68	2.95	3.03	1.70	-	-	-	-
Other Noncurrent Operating Liabilities	114	89	76	77	39	41	29	27
Total Equity & Noncontrolling Interests	53	93	103	144	270	279	112	157
Total Preferred & Common Equity	53	93	103	144	270	279	112	157
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	53	93	103	144	270	279	112	157
Common Stock	1,235	1,141	1,086	1,048	1,006	954	719	692
Retained Earnings	-1,182	-1,048	-983	-904	-737	-675	-608	-535

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	42.53%	440.80%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	-21.38%	-27.89%	-40.76%	-25.72%	-47.66%	-124.62%	-8.55%	0.57%	-196.76%	-12.35%
EBIT Growth	-21.02%	-28.94%	-44.18%	-25.79%	-47.43%	-123.74%	-8.07%	-0.97%	-196.01%	-62.41%
NOPAT Growth	-21.02%	-28.94%	-44.18%	-25.79%	-47.43%	-104.72%	-20.92%	1.38%	-199.51%	-62.13%
Net Income Growth	-20.05%	-27.84%	-43.50%	-26.73%	-50.56%	-120.71%	-6.99%	-6.40%	-122.77%	-103.49%
EPS Growth	-13.66%	-14.57%	-32.56%	-25.27%	-37.81%	-74.78%	9.45%	10.56%	-39.22%	-54.55%
Operating Cash Flow Growth	11.49%	-24.52%	-7.66%	-37.94%	-69.18%	-54.31%	-13.53%	-24.39%	-186.08%	-61.84%
Free Cash Flow Firm Growth	1.36%	8.83%	-79.24%	-26.63%	-116.25%	-31.51%	-43.03%	-8.90%	-221.23%	0.00%
Invested Capital Growth	-518.31%	-221.03%	140.79%	0.04%	-2.13%	-248.18%	16.98%	-38.89%	-233.38%	0.00%
Revenue Q/Q Growth	13.96%	21.11%	94.95%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	8.86%	-20.74%	-17.24%	-26.71%	15.47%	-28.81%	0.00%	0.00%	-18.57%	0.00%
EBIT Q/Q Growth	8.38%	-19.83%	-17.91%	-26.33%	15.23%	-28.66%	0.00%	0.00%	-18.89%	0.00%
NOPAT Q/Q Growth	8.38%	-19.83%	-17.91%	-26.33%	15.23%	-28.66%	0.00%	0.00%	-19.38%	0.00%
Net Income Q/Q Growth	7.63%	-18.54%	-17.05%	-24.83%	14.01%	-28.63%	0.00%	0.00%	-17.06%	0.00%
EPS Q/Q Growth	9.24%	-15.57%	-13.30%	-3.27%	-2.59%	-24.07%	0.00%	0.00%	-10.94%	0.00%
Operating Cash Flow Q/Q Growth	3.14%	-1.97%	1.08%	-8.29%	-3.96%	-20.14%	-13.19%	3.38%	-30.44%	0.00%
Free Cash Flow Firm Q/Q Growth	-5.08%	-0.66%	2.34%	-33.41%	13.66%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	-53.14%	-128.98%	-71.15%	4.30%	-14.10%	-24.89%	0.00%	0.00%	6.97%	0.00%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.37%	90.37%	89.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-69.99%	-82.19%	-347.57%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-72.74%	-85.67%	-359.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-72.74%	-85.67%	-359.33%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-74.47%	-88.41%	-373.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	100.03%	100.40%	100.00%	100.00%	99.95%	99.80%	99.30%	99.29%	98.29%	97.80%
Interest Burden Percent	102.34%	102.78%	104.08%	104.57%	103.85%	101.84%	103.75%	104.82%	100.48%	134.18%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	-231.63%	-159.21%	-298.97%	-201.51%	-70.36%	-76.08%	-350.78%	-151.19%	-79.99%	-26.29%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	-1,763.61%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	-48.51%	-50.41%	-85.77%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	-49.66%	-52.02%	-89.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	-231.63%	-159.21%	-298.97%	-201.51%	-70.36%	-76.08%	-350.78%	-151.19%	-79.99%	-26.29%
Return on Equity Simple (ROE_SIMPLE)	-503.76%	-125.27%	-170.81%	-834.29%	-90.43%	-38.24%	-3,301.50%	-173.14%	-126.10%	-26.29%
Net Operating Profit after Tax (NOPAT)	-196	-162	-126	-87	-69	-47	-23	-19	-19	-6.44
NOPAT Margin	-50.92%	-59.97%	-251.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	-55.87%	-50.90%	-88.76%	-49.85%	-19.97%	-20.55%	-51.20%	-38.96%	-21.15%	-24.04%
Return On Investment Capital (ROIC_SIMPLE)	-78.89%	-43.22%	-60.01%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	8.63%	9.63%	10.39%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	106.65%	119.41%	318.27%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	48.50%	36.20%	115.81%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	164.11%	176.04%	448.94%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-281	-232	-180	-125	-99	-67	-30	-28	-28	-9.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-270	-222	-174	-124	-98	-67	-30	-27	-27	-9.25
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	71.92	19.72	30.57	91.10	26.74	19.96	89.64	7.93	5.99	0.00
Price to Tangible Book Value (P/TBV)	0.00	29.97	84.61	91.10	26.74	19.96	89.64	7.93	5.99	0.00
Price to Revenue (P/Rev)	10.63	13.92	66.94	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	366.14	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	10.31	13.17	64.93	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.37	0.97	0.91	3.14	0.42	0.11	7.37	0.59	0.45	0.00
Long-Term Debt to Equity	3.22	0.93	0.86	3.14	0.42	0.10	3.86	0.40	0.44	0.00
Financial Leverage	-1.31	-1.01	-1.10	-1.34	-1.15	-1.15	-1.76	-1.33	-1.10	-1.03
Leverage Ratio	4.66	3.06	3.35	2.12	1.39	1.31	2.89	1.93	1.28	1.06
Compound Leverage Factor	4.77	3.15	3.49	2.21	1.44	1.34	2.99	2.02	1.29	1.42
Debt to Total Capital	77.10%	49.13%	47.76%	75.85%	29.81%	10.03%	88.05%	37.27%	31.11%	0.00%
Short-Term Debt to Total Capital	3.33%	1.71%	2.81%	0.00%	0.00%	1.31%	41.94%	12.27%	0.86%	0.00%
Long-Term Debt to Total Capital	73.77%	47.43%	44.95%	75.85%	29.81%	8.72%	46.11%	25.00%	30.25%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	22.90%	50.87%	52.24%	24.15%	70.19%	89.97%	11.95%	62.73%	68.89%	100.00%
Debt to EBITDA	-0.71	-0.83	-0.58	-0.40	-0.49	-0.30	-0.23	-0.36	-0.35	0.00
Net Debt to EBITDA	0.46	0.91	0.58	0.30	1.38	3.01	0.24	0.88	0.98	0.00
Long-Term Debt to EBITDA	-0.68	-0.80	-0.54	-0.40	-0.49	-0.26	-0.12	-0.24	-0.35	0.00
Debt to NOPAT	-0.98	-1.14	-0.80	-0.56	-0.70	-0.42	-0.30	-0.52	-0.51	0.00
Net Debt to NOPAT	0.63	1.24	0.80	0.43	1.95	4.25	0.31	1.27	1.39	0.00
Long-Term Debt to NOPAT	-0.94	-1.10	-0.75	-0.56	-0.70	-0.37	-0.16	-0.35	-0.49	0.00
Altman Z-Score	1.63	3.60	5.44	1.49	22.41	50.11	-12.40	-0.59	1.51	0.00
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.11	3.63	2.54	3.75	7.85	9.00	1.41	2.90	5.30	18.63
Quick Ratio	1.99	3.46	2.47	3.75	7.85	8.98	1.29	2.79	5.11	18.25
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-141	-143	-156	-87	-69	-32	-24	-17	-16	-4.85
Operating Cash Flow to CapEx	-47,559.26%	-24,927.84%	-16,597.01%	-35,138.31%	-170,962.87%	-287,668.62%	-91,918.59%	-267,444.45%	-20,353.00%	-36,835.81%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	-55.29	0.00	0.00	0.00	0.00	-1.98
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	-62.92	0.00	0.00	0.00	0.00	-3.04
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-62.95	0.00	0.00	0.00	0.00	-3.05
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.67	0.59	0.24	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	3.26	4.08	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	2.16	2.68	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	539.43	345.15	99.49	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.19	0.24	0.09	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Sales Outstanding (DSO)	112.06	89.37	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	169.15	136.22	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,924.37	1,550.29	3,956.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Cash Conversion Cycle (CCC)	-1,643.17	-1,324.70	-3,956.17	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	-66	-11	8.87	-22	-22	-21	-6.12	-7.37	-5.31	-1.59
Invested Capital Turnover	-10.00	-290.03	-7.77	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	-56	-20	31	0.01	-0.45	-15	1.25	-2.06	-3.72	-1.59
Enterprise Value (EV)	3,977	3,564	3,249	1,387	2,907	3,367	77	108	102	0.00
Market Capitalization	4,100	3,766	3,349	1,424	3,042	3,567	84	133	129	0.00
Book Value per Share	$1.18	$4.04	$2.52	$0.41	$3.06	$5.18	$0.03	$0.71	$1.13	$3.89
Tangible Book Value per Share	($0.04)	$2.66	$0.91	$0.41	$3.06	$5.18	$0.03	$0.71	$1.13	$3.89
Total Capital	249	375	210	65	162	199	7.85	27	31	46
Total Debt	192	184	100	49	48	20	6.91	9.93	9.74	0.00
Total Long-Term Debt	184	178	94	49	48	17	3.62	6.66	9.47	0.00
Net Debt	-123	-202	-101	-37	-136	-200	-7.06	-24	-27	-48
Capital Expenditures (CapEx)	0.27	0.58	0.70	0.31	0.05	0.02	0.03	0.01	0.10	0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-52	-14	-46	-23	-23	-21	-6.28	-7.63	-5.52	-1.64
Debt-free Net Working Capital (DFNWC)	263	372	155	63	161	198	7.68	26	31	46
Net Working Capital (NWC)	255	365	149	63	161	196	4.39	23	31	46
Net Nonoperating Expense (NNE)	91	77	61	43	34	21	7.97	9.93	7.92	5.77
Net Nonoperating Obligations (NNO)	-123	-202	-101	-37	-136	-200	-7.06	-24	-27	-48
Total Depreciation and Amortization (D&A)	11	9.41	5.89	1.15	0.86	0.69	0.42	0.51	0.09	0.05
Debt-free, Cash-free Net Working Capital to Revenue	-13.51%	-5.31%	-91.65%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	68.25%	137.40%	309.73%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	66.10%	135.04%	297.94%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($5.99)	($5.27)	($4.60)	($3.47)	($2.77)	($2.01)	($1.15)	($1.27)	($1.42)	($1.02)
Adjusted Weighted Average Basic Shares Outstanding	47.91M	45.43M	40.66M	38.48M	37.41M	37.08M	33.28M	25.49M	19.20M	11.95M
Adjusted Diluted Earnings per Share	($5.99)	($5.27)	($4.60)	($3.47)	($2.77)	($2.01)	($1.15)	($1.27)	($1.42)	($1.02)
Adjusted Weighted Average Diluted Shares Outstanding	47.91M	45.43M	40.66M	38.48M	37.41M	37.08M	33.28M	25.49M	19.20M	11.95M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	($3.47)	($2.77)	($2.01)	($1.15)	($1.27)	($1.42)	($1.02)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	48.77M	47.37M	43.52M	37.62M	37.21M	34.02M	26.88M	22.76M	19.15M	11.95M
Normalized Net Operating Profit after Tax (NOPAT)	-196	-162	-126	-87	-69	-47	-23	-19	-19	-6.44
Normalized NOPAT Margin	-50.92%	-59.97%	-251.53%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-74.45%	-88.06%	-373.99%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	-79.50	0.00	0.00	0.00	0.00	-3.81
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	-55.65	0.00	0.00	0.00	0.00	-2.63
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-79.54	0.00	0.00	0.00	0.00	-3.81
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	-55.69	0.00	0.00	0.00	0.00	-2.64
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.28%	-6.55%	-3.73%	-0.17%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	61.95%	66.04%	81.27%	86.65%	-20.70%	193.50%	243.07%	429.48%	0.00%	0.00%	0.00%
EBITDA Growth	16.42%	27.31%	-0.24%	-20.74%	-1,470.37%	-66.00%	-48.34%	-64.35%	89.07%	-79.17%	-19.63%
EBIT Growth	15.30%	26.11%	-0.81%	-19.97%	-955.46%	-64.02%	-46.47%	-66.04%	83.35%	-83.75%	-26.95%
NOPAT Growth	15.30%	26.11%	-0.81%	-19.97%	-955.46%	-64.02%	-46.47%	-66.04%	83.35%	-83.75%	-26.95%
Net Income Growth	13.08%	24.06%	-3.86%	-18.13%	-509.35%	-61.09%	-38.77%	-62.10%	71.69%	-80.25%	-28.50%
EPS Growth	15.28%	28.37%	-1.52%	-8.44%	-453.85%	-49.31%	-23.36%	-45.28%	74.76%	-60.00%	-15.05%
Operating Cash Flow Growth	18.88%	13.70%	65.21%	45.60%	-818.52%	-10.15%	-135.29%	-65.04%	82.17%	4.43%	15.01%
Free Cash Flow Firm Growth	149.10%	109.82%	173.47%	78.17%	37.49%	32.23%	40.14%	67.41%	-70.33%	-217.80%	-321.64%
Invested Capital Growth	-8,465.13%	-518.31%	-216.99%	-194.19%	-103.34%	-221.03%	20.51%	-39.70%	191.38%	140.79%	235.29%
Revenue Q/Q Growth	2.27%	13.37%	20.19%	16.22%	4.85%	23.77%	23.76%	-50.62%	288.07%	44.67%	91.00%
EBITDA Q/Q Growth	22.42%	-16.61%	20.58%	-16.33%	32.53%	-60.80%	4.34%	-1,413.06%	92.87%	-43.70%	-5.99%
EBIT Q/Q Growth	21.53%	-15.96%	19.76%	-16.01%	31.54%	-58.20%	4.51%	-920.66%	89.36%	-41.27%	-8.25%
NOPAT Q/Q Growth	21.53%	-15.96%	19.76%	-16.01%	31.54%	-58.20%	4.51%	-920.66%	89.36%	-41.27%	-8.25%
Net Income Q/Q Growth	20.69%	-15.96%	18.58%	-16.07%	30.71%	-58.61%	7.40%	-498.77%	81.68%	-36.63%	-8.17%
EPS Q/Q Growth	20.78%	-14.93%	19.76%	-15.97%	33.02%	-62.88%	14.29%	-492.31%	81.94%	-34.58%	-0.94%
Operating Cash Flow Q/Q Growth	-65.54%	-40.64%	38.12%	43.68%	-76.10%	43.30%	3.25%	-850.85%	78.88%	-21.11%	32.14%
Free Cash Flow Firm Q/Q Growth	180.13%	-86.80%	674.39%	76.88%	43.98%	1.23%	-70.64%	33.79%	39.27%	12.75%	7.11%
Invested Capital Q/Q Growth	18.61%	-53.14%	-85.22%	-3,609.98%	94.12%	-128.98%	49.12%	31.41%	113.14%	-71.15%	-25.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	91.94%	91.15%	91.95%	90.76%	91.60%	89.69%	88.70%	90.15%	92.01%	90.60%	88.58%
EBITDA Margin	-44.61%	-58.80%	-57.17%	-86.52%	-86.43%	-134.32%	-103.38%	-133.75%	-4.36%	-237.49%	-239.10%
Operating Margin	-46.91%	-61.14%	-59.78%	-89.54%	-89.70%	-137.39%	-107.49%	-139.31%	-6.74%	-245.85%	-251.76%
EBIT Margin	-46.91%	-61.14%	-59.78%	-89.54%	-89.70%	-137.39%	-107.49%	-139.31%	-6.74%	-245.85%	-251.76%
Profit (Net Income) Margin	-48.91%	-63.08%	-61.67%	-91.03%	-91.14%	-137.92%	-107.62%	-143.83%	-11.86%	-251.29%	-266.08%
Tax Burden Percent	100.00%	100.11%	100.00%	100.00%	100.00%	99.67%	98.92%	99.09%	129.87%	100.00%	100.00%
Interest Burden Percent	104.27%	103.04%	103.16%	101.66%	101.61%	100.71%	101.22%	104.20%	135.52%	102.21%	105.68%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	-25,321.38%	-1,724.41%	0.00%	-495.80%	-538.73%	0.00%	0.00%	-1,127.57%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	-25,308.38%	-1,706.51%	0.00%	-485.37%	-519.75%	0.00%	0.00%	-1,111.81%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	25,212.69%	1,584.57%	0.00%	408.26%	402.95%	0.00%	0.00%	1,067.23%
Return on Equity (ROE)	-282.16%	-231.63%	-171.61%	-108.69%	-139.84%	-159.21%	-87.54%	-135.77%	-250.92%	-298.97%	-60.34%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-418.00%	-318.68%	-756.81%	-1,763.61%	-521.00%
Operating Return on Assets (OROA)	-35.49%	-40.77%	-34.81%	-45.00%	-48.17%	-80.85%	-51.11%	-64.18%	-4.08%	-58.68%	-28.37%
Return on Assets (ROA)	-37.01%	-42.06%	-35.91%	-45.75%	-48.94%	-81.16%	-51.17%	-66.27%	-7.18%	-59.98%	-29.98%
Return on Common Equity (ROCE)	-282.16%	-231.63%	-171.61%	-108.69%	-139.84%	-159.21%	-87.54%	-135.77%	-250.92%	-298.97%	-60.34%
Return on Equity Simple (ROE_SIMPLE)	-523.02%	0.00%	-334.73%	-300.00%	-205.77%	0.00%	-74.89%	-66.16%	-141.95%	0.00%	-101.59%
Net Operating Profit after Tax (NOPAT)	-40	-51	-44	-55	-47	-69	-43	-46	-4.46	-42	-30
NOPAT Margin	-32.84%	-42.80%	-41.84%	-62.68%	-62.79%	-96.17%	-75.24%	-97.52%	-4.72%	-172.10%	-176.23%
Net Nonoperating Expense Percent (NNEP)	-15.50%	-14.81%	-11.26%	-13.00%	-17.90%	-19.75%	-10.42%	-18.98%	-10.53%	-27.96%	-15.76%
Return On Investment Capital (ROIC_SIMPLE)	-16.16%	-20.42%	-	-	-	-18.32%	-	-	-	-20.00%	-
Cost of Revenue to Revenue	8.06%	8.85%	8.05%	9.24%	8.40%	10.31%	11.30%	9.85%	7.99%	9.40%	11.42%
SG&A Expenses to Revenue	99.44%	95.37%	91.22%	118.80%	131.96%	121.36%	143.94%	169.03%	78.45%	252.34%	242.74%
R&D to Revenue	36.87%	46.31%	43.32%	57.19%	49.11%	43.06%	49.78%	44.07%	18.81%	60.29%	88.31%
Operating Expenses to Revenue	138.85%	152.29%	151.72%	180.30%	181.31%	227.07%	196.18%	229.46%	98.75%	336.45%	340.34%
Earnings before Interest and Taxes (EBIT)	-57	-73	-63	-78	-67	-98	-62	-65	-6.37	-60	-42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-54	-70	-60	-75	-65	-96	-60	-62	-4.13	-58	-40
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	106.90	71.92	46.44	37.17	26.22	19.72	12.24	11.23	24.01	30.57	11.43
Price to Tangible Book Value (P/TBV)	0.00	0.00	133.33	93.93	47.03	29.97	16.28	14.89	61.83	84.61	21.36
Price to Revenue (P/Rev)	13.16	10.63	12.75	13.12	15.04	13.92	14.76	17.16	18.56	66.94	70.07
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00	82.72	115.77	137.01	366.14	54.36
Enterprise Value to Revenue (EV/Rev)	12.91	10.31	12.34	12.68	14.47	13.17	13.72	15.77	17.92	64.93	65.14
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	3.64	3.37	2.06	1.84	1.30	0.97	0.68	0.66	1.37	0.91	0.64
Long-Term Debt to Equity	3.48	3.22	1.97	1.77	1.25	0.93	0.66	0.63	1.32	0.86	0.60
Financial Leverage	-1.28	-1.31	-1.02	-1.00	-0.93	-1.01	-0.84	-0.78	-1.01	-1.10	-0.96
Leverage Ratio	5.79	4.66	3.21	3.04	3.65	3.06	2.20	2.69	3.78	3.35	2.28
Compound Leverage Factor	6.04	4.81	3.31	3.09	3.71	3.08	2.23	2.81	5.12	3.42	2.41
Debt to Total Capital	78.45%	77.10%	67.29%	64.81%	56.46%	49.13%	40.59%	39.65%	57.87%	47.76%	39.07%
Short-Term Debt to Total Capital	3.48%	3.33%	2.86%	2.41%	1.93%	1.71%	1.47%	1.37%	2.26%	2.81%	2.71%
Long-Term Debt to Total Capital	74.96%	73.77%	64.42%	62.40%	54.53%	47.43%	39.12%	38.28%	55.61%	44.95%	36.36%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	21.55%	22.90%	32.71%	35.19%	43.54%	50.87%	59.41%	60.35%	42.13%	52.24%	60.93%
Debt to EBITDA	-0.75	-0.71	-0.65	-0.64	-0.66	-0.83	-1.00	-1.11	-1.10	-0.58	-0.68
Net Debt to EBITDA	0.41	0.46	0.46	0.43	0.51	0.91	1.26	1.54	0.66	0.58	0.85
Long-Term Debt to EBITDA	-0.71	-0.68	-0.62	-0.62	-0.64	-0.80	-0.96	-1.07	-1.05	-0.54	-0.63
Debt to NOPAT	-1.02	-0.98	-0.89	-0.89	-0.91	-1.14	-1.36	-1.51	-1.48	-0.80	-0.95
Net Debt to NOPAT	0.57	0.63	0.64	0.59	0.71	1.24	1.72	2.09	0.90	0.80	1.19
Long-Term Debt to NOPAT	-0.98	-0.94	-0.85	-0.85	-0.88	-1.10	-1.31	-1.45	-1.43	-0.75	-0.88
Altman Z-Score	4.42	2.84	3.75	3.31	4.07	4.35	5.08	4.84	4.57	6.63	4.07
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	2.03	2.11	2.44	2.48	3.20	3.63	4.46	4.52	3.02	2.54	4.19
Quick Ratio	1.90	1.99	2.30	2.34	3.01	3.46	4.32	4.39	2.89	2.47	4.11
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	14	4.83	37	-6.37	-28	-49	-50	-29	-44	-73	-83
Operating Cash Flow to CapEx	-12,832.84%	-87,340.00%	-20,701.11%	-57,903.85%	-54,558.16%	-433,742.86%	-14,433.42%	-41,615.79%	-8,198.59%	-15,228.18%	-34,481.82%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.67	0.58	0.50	0.54	0.59	0.48	0.46	0.61	0.24	0.11
Accounts Receivable Turnover	3.29	3.26	3.34	3.11	3.43	4.08	4.53	4.37	0.00	0.00	0.00
Inventory Turnover	2.31	2.16	2.49	2.31	2.11	2.68	3.47	1.67	0.00	0.00	0.00
Fixed Asset Turnover	545.31	539.43	409.26	399.30	331.38	345.15	279.65	266.29	248.49	99.49	54.50
Accounts Payable Turnover	0.20	0.19	0.21	0.20	0.21	0.24	0.26	0.23	0.22	0.09	0.08
Days Sales Outstanding (DSO)	110.99	112.06	109.20	117.55	106.31	89.37	80.63	83.58	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	158.23	169.15	146.70	158.03	173.06	136.22	105.16	218.24	0.00	0.00	0.00
Days Payable Outstanding (DPO)	1,841.94	1,924.37	1,778.48	1,849.36	1,699.86	1,550.29	1,395.57	1,607.53	1,690.30	3,956.17	4,814.76
Cash Conversion Cycle (CCC)	-1,572.71	-1,643.17	-1,522.58	-1,573.79	-1,420.49	-1,324.70	-1,209.78	-1,305.71	-1,690.30	-3,956.17	-4,814.76
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	-54	-66	-43	-23	-0.63	-11	37	25	19	8.87	31
Invested Capital Turnover	-15.81	-10.00	-107.50	404.00	27.46	-290.03	6.59	5.52	-162.02	-7.77	6.40
Increase / (Decrease) in Invested Capital	-53	-56	-80	-48	-20	-20	6.31	-16	40	31	53
Enterprise Value (EV)	5,580	3,977	4,178	3,697	3,631	3,564	3,066	2,877	2,591	3,249	1,672
Market Capitalization	5,688	4,100	4,314	3,823	3,776	3,766	3,298	3,131	2,684	3,349	1,798
Book Value per Share	$1.09	$1.18	$1.94	$2.17	$3.04	$4.04	$5.71	$6.40	$2.57	$2.52	$3.90
Tangible Book Value per Share	($0.09)	($0.04)	$0.67	$0.86	$1.69	$2.66	$4.29	$4.83	$1.00	$0.91	$2.09
Total Capital	247	249	284	292	331	375	454	462	265	210	258
Total Debt	194	192	191	189	187	184	184	183	154	100	101
Total Long-Term Debt	185	184	183	182	180	178	177	177	148	94	94
Net Debt	-107	-123	-136	-126	-145	-202	-232	-254	-93	-101	-127
Capital Expenditures (CapEx)	0.34	0.03	0.09	0.05	0.10	0.01	0.37	0.13	0.07	0.18	0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-42	-52	-36	-32	-8.61	-14	-13	-26	-37	-46	-28
Debt-free Net Working Capital (DFNWC)	259	263	291	283	323	372	404	411	210	155	199
Net Working Capital (NWC)	251	255	283	276	316	365	397	405	204	149	192
Net Nonoperating Expense (NNE)	20	24	21	25	21	30	19	22	6.76	19	15
Net Nonoperating Obligations (NNO)	-107	-123	-136	-126	-145	-202	-232	-254	-93	-101	-127
Total Depreciation and Amortization (D&A)	2.80	2.78	2.73	2.63	2.45	2.19	2.37	2.60	2.25	2.04	2.13
Debt-free, Cash-free Net Working Capital to Revenue	-9.62%	-13.51%	-10.72%	-11.03%	-3.43%	-5.31%	-5.72%	-14.28%	-25.39%	-91.65%	-110.73%
Debt-free Net Working Capital to Revenue	60.01%	68.25%	86.00%	97.26%	128.61%	137.40%	180.71%	225.24%	145.07%	309.73%	775.74%
Net Working Capital to Revenue	58.02%	66.10%	83.59%	94.84%	126.06%	135.04%	177.72%	221.77%	140.93%	297.94%	748.46%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.22)	($1.54)	($1.34)	($1.67)	($1.44)	($2.15)	($1.32)	($1.54)	($0.26)	($1.44)	($1.07)
Adjusted Weighted Average Basic Shares Outstanding	48.87M	47.91M	48.14M	47.57M	47.39M	45.43M	47.12M	43.67M	43.52M	40.66M	41.70M
Adjusted Diluted Earnings per Share	($1.22)	($1.54)	($1.34)	($1.67)	($1.44)	($2.15)	($1.32)	($1.54)	($0.26)	($1.44)	($1.07)
Adjusted Weighted Average Diluted Shares Outstanding	48.87M	47.91M	48.14M	47.57M	47.39M	45.43M	47.12M	43.67M	43.52M	40.66M	41.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	49.24M	48.77M	48.46M	48.00M	47.50M	47.37M	47.32M	47.19M	43.57M	43.52M	43.43M
Normalized Net Operating Profit after Tax (NOPAT)	-40	-51	-44	-55	-47	-69	-43	-46	-4.46	-42	-30
Normalized NOPAT Margin	-32.84%	-42.80%	-41.84%	-62.68%	-62.79%	-96.17%	-75.24%	-97.52%	-4.72%	-172.10%	-176.23%
Pre Tax Income Margin	-48.91%	-63.00%	-61.67%	-91.03%	-91.14%	-138.37%	-108.80%	-145.15%	-9.13%	-251.29%	-266.08%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.43%	-0.28%	-0.16%	-0.74%	0.00%	-6.55%	-7.76%	-10.21%	0.00%	-3.73%	0.00%

Frequently Asked Questions About Axsome Therapeutics' Financials

When does Axsome Therapeutics's financial year end?

According to the most recent income statement we have on file, Axsome Therapeutics' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Axsome Therapeutics' net income changed over the last 9 years?

Axsome Therapeutics' net income appears to be on an upward trend, with a most recent value of -$287.22 million in 2024, rising from -$12.21 million in 2015. The previous period was -$239.24 million in 2023. See where experts think Axsome Therapeutics is headed by visiting Axsome Therapeutics' forecast page.

What is Axsome Therapeutics's operating income?

Axsome Therapeutics's total operating income in 2024 was -$280.56 million, based on the following breakdown:

Total Gross Profit: $352.39 million
Total Operating Expenses: $632.95 million

How has Axsome Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' total revenue changed from $0.00 in 2015 to $385.69 million in 2024, a change of 38,569,300,000.0%.

How much debt does Axsome Therapeutics have?

Axsome Therapeutics' total liabilities were at $511.48 million at the end of 2024, a 28.8% increase from 2023, and a 19,334.0% increase since 2015.

How much cash does Axsome Therapeutics have?

In the past 9 years, Axsome Therapeutics' cash and equivalents has ranged from $13.97 million in 2018 to $386.19 million in 2023, and is currently $315.35 million as of their latest financial filing in 2024.

How has Axsome Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' book value per share changed from 3.89 in 2015 to 1.18 in 2024, a change of -69.7%.

Related Companies

This page (NASDAQ:AXSM) was last updated on 5/28/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Axsome Therapeutics (AXSM) Financials

Frequently Asked Questions About Axsome Therapeutics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Axsome Therapeutics (AXSM) Financials

Annual Income Statements for Axsome Therapeutics

Quarterly Income Statements for Axsome Therapeutics

Annual Cash Flow Statements for Axsome Therapeutics

Quarterly Cash Flow Statements for Axsome Therapeutics

Annual Balance Sheets for Axsome Therapeutics

Quarterly Balance Sheets for Axsome Therapeutics

Annual Metrics And Ratios for Axsome Therapeutics

Quarterly Metrics And Ratios for Axsome Therapeutics

Frequently Asked Questions About Axsome Therapeutics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools